Document Detail


Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy.
MedLine Citation:
PMID:  9647028     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when associated with primary biliary cirrhosis and their response to ursodeoxycholic acid treatment. We evaluated the prevalence, natural history, and response to ursodeoxycholic acid therapy of these conditions coassociated with primary biliary cirrhosis. METHODS: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13-15 mg/ kg/day), were included. Patients were assessed at study entry and annually. RESULTS: At entry, 77/180 patients (43%) had one of the four conditions, and 18/180 patients (10%) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32%). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9% per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features. CONCLUSIONS: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease.
Authors:
T H Zukowski; R A Jorgensen; E R Dickson; K D Lindor
Related Documents :
11814708 - Interactions of combined bile acids on hepatocyte viability: cytoprotection or synergism.
16347578 - Adsorption of lithocholic acid to fusarium equiseti m41 as an essential process in its ...
2767508 - Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirr...
6631218 - Formation of ursodeoxycholic acid from chenodeoxycholic acid in the human colon: studie...
22166918 - A microfluidic device for the automated derivatization of free fatty acids to fatty aci...
8538938 - Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  93     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-07-13     Completed Date:  1998-07-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  958-61     Citation Subset:  IM    
Affiliation:
Mayo Foundation, Rochester, Minnesota, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arthritis / complications,  drug therapy
Autoimmune Diseases / complications,  drug therapy*
Cholagogues and Choleretics / therapeutic use*
Female
Humans
Liver Cirrhosis, Biliary / complications,  drug therapy*
Male
Middle Aged
Prospective Studies
Raynaud Disease / complications,  drug therapy
Sjogren's Syndrome / complications,  drug therapy
Thyroiditis, Autoimmune / complications,  drug therapy
Ursodeoxycholic Acid / therapeutic use*
Chemical
Reg. No./Substance:
0/Cholagogues and Choleretics; 128-13-2/Ursodeoxycholic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Significance of elevated IgG anticardiolipin antibody levels in patients with Budd-Chiari syndrome.
Next Document:  The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis afte...